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deletion. 93% of mutation carriers developed at least one 
malignancy (mainly breast cancer and sarcomas), with a 
mean age at diagnosis of the first tumor of 30.2 years. Two 
missense mutations acted as dominant-negative. The novel 
inframe mutation c.437_445del was located in the DNA-
binding domain. This mutation segregated with cancer in 
the family, and both high expression of the protein and loss 
of the wild-type TP53 allele were detected in the tumor of 
the carrier. We have found a novel inframe deletion in TP53 
that likely results in the loss of p53 function and acts in a 
non-dominant negative way, although further studies are 
necessary to clarify this issue. The identification of novel 
TP53 alterations is crucial for a personalized cancer-risk 
management of the Li-Fraumeni syndrome.
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Introduction
Li-Fraumeni syndrome (LFS) is a hereditary predisposi-
tion to cancer affecting adults and children that is caused by 
germline mutations in the TP53 tumor suppressor gene [1]. 
p53 is a DNA damage response protein, and its inactivation 
could be expected to result in subsequent genomic insta-
bility. As it is widely known, p53 is the major tumor sup-
pressor protein that serves as a gatekeeper of cellular fate 
in multicellular organisms, and functions as a transcription 
factor of genes involved in the regulation of the cell cycle, 
DNA repair, apoptosis, cellular metabolism and senes-
cence [2]. Between 50–70% of ‘classic’ LFS families carry 
a mutant TP53, and penetrance is nearly 100% by age 70. 
Carriers of a germline TP53 mutation have a 50% chance of 
developing cancer before the age of 40, as compared with a 
Abstract Li-Fraumeni syndrome (LFS) is an autoso-
mal dominant, inherited tumor predisposition syndrome 
associated with heterozygous germline mutations in the 
TP53 gene. The molecular diagnosis of LFS is important 
to develop strategies for early detection and access to the 
genetic counseling. Our study evaluated germline TP53 
mutations in Spanish families with a history suggestive of 
LFS. Germline TP53 alterations in 22 families with a his-
tory suggestive of LFS were evaluated by Sanger sequenc-
ing and multiplex ligation-dependent probe amplification. 
Loss of heterozygosity analysis and immunohistochemis-
try of the protein in the tumor were performed in order to 
evaluate the pathogenicity of a novel alteration detected. 
A total of seven TP53 mutations were detected, six point 
mutations (4 missense and 2 nonsense) and a novel inframe 
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1% in the general population, and 90% of the carriers are 
diagnosed with cancer by the age of 60 years [1]. This gene 
predisposes to a wide spectrum of tumors, with an inci-
dence rate of 50% for breast cancer, 15% for soft tissue sar-
comas, 6% for brain tumors and 5% for osteosarcomas [3]. 
Furthermore, other types of cancer, including lung, gas-
tric, ovarian, colorectal cancer and early-onset melanoma, 
have also been described in excess in some families [1, 4]. 
In female TP53 mutation carriers, early-onset breast can-
cer is the most frequent malignancy, with an 18- to 60-fold 
increased risk when compared to the general population. In 
contrast, TP53 germline mutations only account for 4% of 
breast cancer families, with an average age at diagnosis of 
30 years [5].
The diagnosis of classic LFS is based on an evolving set 
of clinical classification criteria that has been established 
using aspects of family history, type of tumors and early 
age at diagnosis, indicating when TP53 genotyping should 
be evaluated. However, TP53-positive families have been 
detected with incomplete clinical LFS features, leading to 
several definitions of Li-Fraumeni-like (LFL) syndrome. 
According to the NCCN guidelines, two criteria are consid-
ered to facilitate the identification of individuals for TP53 
gene mutation testing: classic LFS and Chompret criteria 
(last updated in 2015) [6–8]. The molecular diagnosis of 
LFS is important in order to develop strategies for early 
detection, and it is significant for the clinical practice in a 
genetic counseling context. All patients should have cancer 
genetic counseling prior to initiating the testing process, 
and access to long-term counseling to support the educa-
tional and psychosocial needs of LFS patients and their 
families [4]. Screening protocols can detect early-stage 
disease and improve the outcome in LFS patients [4, 9]. 
Recently, a study has showed that a surveillance protocol 
for TP53 mutation carriers is associated with early tumor 
detection and improves long-term survival [10, 11]. In a 
study analyzing the largest worldwide series of patients 
suggestive of LFS, Bougeard et al. pointed out the contri-
bution of chemotherapy and radiotherapy to the increase of 
secondary tumor risk. Moreover, they observed a clinical 
severity gradient of germline TP53 mutations, suggesting 
that the clinical management of the carriers might be strati-
fied according to the class of the mutation, although this 
should be confirmed in subsequent studies [8].
The molecular study of LFS has been focusing on the 
genetic screening of exons 5–8 of TP53, where 95% of the 
mutations are detected [12], although other mutations can 
occur outside this region. Currently, the molecular study is 
performed by sequencing the entire coding region. DNA 
sequencing and immunohistochemical staining have been 
used to assess TP53 status. Most TP53 alterations are point 
missense mutations that lead to the synthesis of a stable but 
inactive protein that accumulates in the nucleus of tumor 
cells, enabling p53 detection with routine IHC. For this 
reason, immunohistochemistry (IHC) is commonly used to 
evaluate mutant p53 status: overexpression of p53 is asso-
ciated with a mutation, and the lack of expression with 
wild-type p53. However, the correlation between the accu-
mulation of p53 and TP53 mutations is about 80%, since 
frameshift mutations do not lead to p53 accumulation [9].
In this study, we included Spanish cancer families that 
met either the criteria for classic LFS or Chompret criteria. 
Seven pathogenic variants were detected in our population, 
one of which had never been reported in the literature.
Materials and methods
Study population
Forty five members from 22 families with a history sugges-
tive of LFS and recruited at the Genetic Counseling Unit 
of our Hospital (2000–2015) were analyzed. This study 
was revised and approved by the Ethics Committee of the 
Clínico San Carlos Hospital of Madrid and was conducted 
in accordance with the Declaration of Helsinki. All mem-
bers of the families who contributed to this study or their 
legal representatives gave their informed consent. Families 
were classified into two groups: classic LFS and Chompret 
criteria (updated by Bougeard et al.) [8]. Classic LFS cri-
teria included families with a proband diagnosed of a sar-
coma before 45 years of age, a first-degree relative with 
a cancer diagnosed at age <45 years, and a first-degree 
or second-degree relative presenting any cancer with age 
of onset <45 or a sarcoma at any age. Chompret crite-
ria included probands with a tumor belonging to the LFS 
tumor spectrum (e.g. sarcoma, CNS tumor, premenopausal 
breast cancer, ACC) before age 46 AND at least one first- 
or second-degree relative with a LFS tumor (except breast 
cancer if the proband had breast cancer) before 56 years old 
OR with multiple tumors; OR a proband with multiple pri-
mary tumors (except multiple breast tumors), two of which 
belonged to the LFS tumor spectrum and the first occurring 
before age 46 years; OR a patient with ACC, choroid plexus 
tumor, or rhabdomyosarcoma of embryonal anaplastic sub-
type, irrespective of the family history; OR breast cancer 
before age 31 years. TP53 mutation testing was offered to 
family members of a proven TP53 mutation carrier. Clini-
cal data were updated until 2015 for each TP53 mutation 
carrier. The histological subtypes of cancer were confirmed 
in the medical and pathology records. The sequence of the 
TP53 gene was also analyzed in a group of families that did 
not fulfill the previous criteria, but that included at least 
a sarcoma at any age. In this group no alterations were 
found, in agreement with another study [13]. This seems to 
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indicate that TP53 testing should not be recommended in 
this type of families.
DNA extraction
Germline DNA was isolated from peripheral blood lym-
phocytes by the salting out procedure [14]. Tumor DNA 
extraction was performed using the “QIAamp DNA FFPE 
Tissue” Kit (Qiagen), following the manufacturer’s instruc-
tions. The tumor tissue was microdissected on a corre-
sponding unstained slide for subsequent DNA isolation. 
Five serial 5–7 µm-thick sections were cut from tumor par-
affin blocks.
DNA quantity and quality were assessed by Nanodrop 
(ND1000), and all samples were diluted to a final concen-
tration of 50 ng/µl.
Immunohistochemistry (IHC)
Tumor tissue sections of paraffin-embedded specimens 
were selected for p53 IHC staining using a recombinant 
human wild-type p53 antibody (DO-7; Dako). After the 
deparaffinization and hydration of the sections, antigens 
were unmasked by heat in EDTA buffer. Immunostain-
ing was performed using the UltraVision LP Large Vol-
ume Detection System AP Polymer (Thermo Scien-
tific, Waltham, MA, USA). Negative control slides were 
included. Nuclear staining was considered a positive reac-
tion. The extent of the staining was estimated to the nearest 
10% level of positive tumor cells. The slides were reevalu-
ated by two pathologists. Each section was scanned at ×100 
and ×400 magnification by microscope (Olympus BX51).
TP53 gene sequencing
Exons 2–11 and the flanking regions of the TP53 gene 
were amplified by PCR using specific primers with 100 ng 
of DNA. PCR primers had a common sequence to unify 
the sequencing process, which used the same forward and 
reverse primers for all exons (primers are summarized in 
Supplementary Table  1). The extended PCR products 
were purified and sequenced using the ABI3130 auto-
mated sequencer (Applied Biosystems, USA). Sequencing 
was carried out using the fluorescent Big-Dye Terminator 
v.1.1 cycle sequencing Kit (Applied Biosystems, Foster 
City, CA, USA) according to the manufacturer’s protocol. 
The NCBI reference genomic sequence used for TP53 was 
NC_000017.10.
Mutilplex ligation-dependent probe amplification 
(MLPA)
Large deletions or genomic rearrangements of patients 
were analyzed by a commercial MLPA kit (SALSA MLPA 
probemix P056-B1 TP53, MRC Holland) according to the 
manufacturer’s protocols. DNA (100  ng) extracted from 
peripheral blood was used. MLPA PCR products were sep-
arated on the ABI3130 instrument (Applied Biosystems) 
and peak heights for each PCR product were compared to 
a normal sample using the Coffalyser software to determine 
gene dosage for each individual exon.
Analysis of loss of heterozygosity (LOH) at the 17q11.2 
locus
The microsatellite marker D17S250 was used to determine 
the LOH at the 17q11.2 locus using a fluorescent PCR in 
both germline and tumor DNA. Products were analyzed 
in the ABI310 genetic analyzer and the area ratio between 
tumor DNA and wild-type DNA was calculated to deter-
mine the allelic loss. Area ratios below 0.5 were consid-
ered LOH. Loss of heterozygosity was also studied through 
DNA tumor sequencing. Details of the primers are summa-
rized in Supplementary Table 2.
Data analysis and in silico predictions
The effects of TP53 alterations on the protein structure and 
function were identified using ClinVar and the IARC TP53 
Database R18 (April 2016). MutationTaster was used to 
predict the possible impact of DNA changes in TP53 with 
default settings. The Rasmol (v2.7.2) program was used for 
the visualization of p53’s 3D structure and the evaluation of 
the impact of an alteration on the p53 protein. This analysis 
was based on conformational parameters for amino acids 
in helixes, β-sheets and random coil regions from proteins 
[15]. The effect of mutations on splicing was predicted 
using Human Splicing Finder [16]. The frequencies in con-
trol cohorts were examined in individuals from the Exome 
Variant Server (Exome Variant Server, NHLBI GO Exome 
Sequencing Project (ESP), Seattle, WA (URL: http://evs.
gs.washington.edu/EVS/) [date (April, 2016) accessed]) 
and ExAC (Exome Aggregation Consortium (ExAC), 
Cambridge, MA (URL: http://exac.broadinstitute.org) [date 
(April, 2016) accessed]). The reference sequences used 
were: GenBank NC_000017.10 (genomic), NM_000546.5 
(cDNA) and UniProt P04637 (protein).




The germline mutational status of the entire coding 
region of TP53 was analyzed in 22 families (45 mem-
bers) with history suggestive of LFS. Among these, five 
families fulfilled the classic LFS criteria and 17 families 
fulfilled the Chompret criteria. In addition, all classic 
LFS families also fulfilled the Chompret criteria. TP53 
mutations were detected in a total of seven families: 
four LFS and three Chompret families. Table  1 shows 
clinical and molecular data from the studied members. 
Large deletions and insertions analyzed by MLPA were 
not detected. Twenty-six members of the TP53-positive 
families were studied, 14 of whom were mutation carri-
ers (10 in LFS and 4 in Chompret families). The mutation 
detection rate was 80% for LFS, and 18% for Chompret 
criteria.
The mean age at tumor diagnosis was 35.1 years, the first 
tumor in mutation carriers being diagnosed at a mean age 
of 30.2 years. The age of tumor onset was more homogene-
ous in females than in males (Fig.  1a, b). Thirteen TP53 
mutation carriers (93%) developed at least one malignancy 
(9 females and 4 males), with a total of 18 tumors. Multi-
ple primary tumors were diagnosed in 30.1% of the carri-
ers. Tumor distribution in the mutation carriers is shown in 
Fig. 2. Sarcomas were the most frequent tumors in males 
(60%), whereas females were mainly affected of breast can-
cer (54%, being the first tumor in 78% of the cases).
Table 1  Clinical characteristics and TP53 status only of the members analyzed from the TP53-positive families
The NCBI reference genomic sequence used for TP53 was NM_000546.5
LFS Classical Li-Fraumeni syndrome criteria, Chompret chompret criteria revised in 2015, F female, M male, B breast cancer, B2 bilateral breast 
cancer, Me Melanoma, Ne neuroendocrine tumor, STS soft tissue sarcoma, O Ovarian cancer, OS Osteosarcoma, NA not applicable, ND IHC not 
done
**Young asymptomatic mutation carrier (27 years-old and 5 years-old in families 12 and 30, respectively). The member of the family with the 
malignant Phyllodes tumor is shown in bold
Family ID Criteria Gender Family member Tumor type-age
of onset
TP53 status TP53 IHC in tumor
4 Chompret F Cancer B-26 c.1015G > C positive
F Asymptomatic – wt NA
M Asymptomatic – wt NA
F Asymptomatic – wt NA
F Asymptomatic – wt NA
8 Chompret M Cancer Cp-4 c.743G > A ND
12 Chompret F Cancer OS-23 c.586C > T Positive
M Asymptomatic** – c.586C > T NA
15 LFS and Chompret F Cancer B-34/STS-36/O-39 c.916C > T Positive
M Cancer STS-37 c.916C > T Positive
F Asymptomatic – wt NA
29 LFS and Chompret F Cancer B-31/STS-43 c.799C > T Positive
F Cancer B-34 c.799C > T Positive
F Cancer Ne-27 wt ND
F Asymptomatic – wt NA
F Asymptomatic – wt NA
30 LFS and Chompret F Cancer STS-28 c.437_445del Positive
F Cancer B2-45/O-49 c.437_445del Positive
F Cancer B-30 c.437_445del Positive
F Cancer B-30 c.437_445del Positive
M Cancer Me-58/STS-58 c.437_445del Positive
F Asymptomatic – wt NA
M Asymptomatic** – c.437_445del NA
32 LFS and Chompret M Cancer STS-12 c.733G > A Positive
F Cancer B-32 wt ND
F Asymptomatic – wt NA
F Asymptomatic – wt NA
571A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome…
1 3
Germline alterations detected in the TP53 gene
Seven germline TP53 alterations were detected in the index 
cases from seven different TP53-positive families. Addi-
tional information about the family histories is shown in 
Supplementary Table  3. The alterations detected corre-
sponded to six point mutations (4 missense and 2 nonsense) 
and a novel inframe deletion. The sequence of the inframe 
deletion is shown in Fig.  3 (a and b panels). Among the 
seven germline mutations found, five affected the DNA-
binding domain, one affected the tetramerization domain 
and one affected the C-terminal domain. Family mem-
bers with missense mutations detected in the p53 DNA-
contact residues (exon 7) showed an early tumor onset, 
developing malignances at ages of four (choroid plexus 
tumor; c.743G > A) and 12 years (sarcoma; c.733G > A). 
Details about the germline TP53 alterations identified were 
obtained using ClinVar and the IARC TP53 Database, with 
the exception of the inframe deletion that had not been 
reported in these databases (Table 2). In addition, the del-
eterious effect on the protein function and structure was 
predicted for all detected mutations by the MutationTaster 
program. Splice sites were not affected by the mutations 
(Human Splicing Finder program). Finally, Supplemen-
tary Fig.  1 shows how the different p53 protein isoforms 
are affected by each alteration. In control cohorts from 
the ExAc database (non Finnish European) and from the 
Exome Variant Server (European American), our identified 
mutations showed minor allele frequencies of <0.01%.
Novel TP53 mutation detected in LFS family ID30
Family ID30 was compatible with Hereditary Breast and 
Ovarian Cancer Syndrome, and so the BRCA1/BRCA2 
Fig. 1  a Age at tumor diag-
nosis, and b age of first tumor 
onset in TP53 mutation carriers 
in females and males
Fig. 2  Tumor distribution of TP53 mutation carriers in the total series, females and males
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genes were studied in germline DNA. However, germline 
mutations and large rearrangements—analyzed according 
to previous studies [17, 18]—were not found for either 
gene (data not shown and available upon request). Some 
years later, a 28-year-old member was diagnosed of a 
malignant Phyllodes tumor of the breast, and the study of 
the TP53 gene was thus proposed. High levels of the p53 
protein were detected in tumor tissue using an IHC anal-
ysis (Fig.  3c). Sequencing of the TP53 gene was there-
fore performed in germline DNA, showing a deletion of 
nine nucleotides in exon 5 (c.437_445del; p.(Trp146_
Asp148del)). This deletion produced the lack of three 
amino acids, though maintaining the open reading frame 
(Fig. 3a, b).
Fig. 3  Study of the inframe deletion c.437_445del in exon 5 of 
TP53 found in our ID30 family. Panel a and b wild-type and mutant 
sequences. Panel c staining of the Phyllodes tumor with the anti-p53 
DO-7. Neoplastic tissue shows strong nuclear staining. Panels d and e 
LOH of one allele is shown by the sequence and the D17S250 micro-
satellite study in the tumor
Table 2  Molecular data of the TP53 alterations detected in our families
The NCBI reference genomic sequence used for TP53 was NM_000546.5. NA Not applicable, NDBL non-DNA-binding loop, L loop
*Stop codon in the protein as HGVS rules
Nucleotide muta-
tion






Inframe deletion DNA binding NDBL/beta-sheet NA Disease causing
c.586C > T 6 p.R196* Nonsense DNA binding NDBL/beta-sheet Pathogenic Disease causing
c.733G > A 7 p.G245S Missense DNA binding L2/L3 Pathogenic Disease causing
c.743G > A 7 p.R248Q Missense DNA binding L2/L3 Pathogenic Disease causing
c.799C > T 8 p.R267W Missense DNA binding NDBL/beta-sheet Likely pathogenic Disease causing
c.916C > T 8 p.R306* Nonsense NA C-term Pathogenic Disease causing
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Moreover, the loss of heterozygosity was analyzed 
through TP53 sequencing in DNA from microdissected 
tumor cells and through microsatellite study (Fig.  3d, e). 
The 17S250 locus (17q11.2) was used to estimate the LOH 
between the blood sample and the tumor sample (R = 0.5). 
Both studies suggested a loss of the wild-type allele.
The in silico analysis by MutationTaster predicted this 
mutation to be disease causing. The deletion included the 
end of a beta sheet (which consists of six amino acids, from 
Cys141 to Trp146) and the surrounding region (Supple-
mentary Fig.  2a). An in silico analysis with Rasmol was 
performed in order to evaluate the impact of this deletion 
on the protein structure. The deletion was located in the 
DNA-binding domain, but the amino acids involved did not 
seem to have a direct interaction with the DNA (Supple-
mentary Fig. 2b). The predictive factors for the secondary 
structure of the mutant protein suggested a stabilization of 
the beta sheet, while the surrounding aperiodic structure 
would comprise two residues less. In this sense, important 
changes in the 3D structure of the mutant protein were not 
predicted.
On the other hand, a segregation study of this variant 
within the ID30 family was performed. The variant coseg-
regated with cancer in the family (Fig. 4); the deletion was 
detected in a woman with malignant Phyllodes tumor at 28 
years old, in a deceased woman with bilateral breast can-
cer and ovarian cancer at 45 and 49 years respectively, in 
two women with breast cancer at 30 years, in a man with 
melanoma and sarcoma at 58 years and in an asymptomatic 
5-year-old child. Moreover, the alteration was not detected 
in a healthy 49 years woman.
Discussion
Germline TP53 mutations have been observed in 50–70% 
of the families with Li-Fraumeni syndrome, a dominant 
inherited cancer syndrome with a high rate of early-onset 
Fig. 4  Pedigree of the family with the novel alteration identified 
(c.437_445del, p.(Trp146_Asp148del)). The different cancer types 
are indicated with different black colored sections. The result of the 
genetic study of TP53 (+: presence of deletion/−: absence of dele-
tion), age at diagnosis (brackets) and age at time of the last clinical 
revision (y) or death (d–y) are also shown
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breast cancer as well as other multiple tumor types (6). In 
this work, we have investigated germline TP53 mutations 
in 22 Spanish cancer families that met either the criteria 
for classic LFS or Chompret criteria (updated in 2015). By 
doing so, seven germline pathogenic variants were identi-
fied. In our population, the highest TP53 mutation rate was 
detected in individuals who fulfilled the LFS criteria.
In the mutation carriers from our study, the tumor spec-
trum and age of onset were in line with previous studies 
[4]. The most frequent tumors in TP53 mutation carriers 
were breast cancers and sarcomas. Breast cancers were 
diagnosed at an early age (26–34 years), except for one 
case with a bilateral breast cancer at 45 years. In 71% of 
the sarcomas, the age of distribution was between ages 20 
and 40, which is according with a previous study analyzing 
germline TP53 mutations in an adult-onset sarcoma cohort 
[19].
As far as the germline mutations are concerned, seven 
pathogenic variants were detected, including four mis-
sense mutations (c.733G > A, c.743G > A, c.799C > T and 
c.1015G > C), two nonsense mutations (c.586C > T and 
c.916C > T) and a novel inframe deletion (c.437_445del) 
not reported previously. TP53 encodes different p53 pro-
tein isoforms, resulting from alternative splicing, alterna-
tive promoter usage, and alternative initiation of transla-
tion. N-terminal and C-terminal p53 isoforms can inhibit 
or enhance the canonical p53 activity, respectively, and are 
often deregulated in cancer [20]. The mutations identified 
in our study affect the majority of p53 isoforms, as do other 
mutations within exons 5–8 described in the literature, 
which represent 95% of the TP53 alterations. Nevertheless, 
more studies are necessary regarding the effects that muta-
tions affecting different isoforms have on the p53 pathway.
The alteration in exon 5 (c.437_445del; p.(Trp147_
Asp148del)) had not been reported in the literature and 
involved the loss of three amino acids in the DNA-binding 
domain of the p53 protein, but did not seem to be crucial to 
bind specific DNA. In order to evaluate the pathogenicity 
of this mutation, in silico studies were performed. Muta-
tionTaster considered this variant as pathogenic, while the 
3D analysis did not clarify this point. Immunohistochemis-
try in the malignant Phyllodes tumor showed a high expres-
sion of the protein similar to that seen in patients with path-
ogenic point missense mutations, due to the accumulation 
of p53. Bearing in mind that the mutation cosegregated 
with cancer in different family members, our results sug-
gest that the inframe deletion shows a concordance with a 
pathogenic mutation.
Most tumor suppressors require the loss of both alleles 
for tumor development, but p53 hotspot mutations in just 
one allele result in severe loss of function. Mutations 
described in TP53 are mostly missense and may act in a 
dominant-negative fashion, blocking the normal wild-type 
functions. Thus, transgenic mice expressing mutated p53 
have higher incidence of tumor formation compared to 
p53+/− mice [21]. Notably, LFS patients with mutations in 
the p53 DNA-contact residues have a decreased rate of loss 
of heterozygosity, suggesting that the missense mutations 
in one allele that make p53 incapable of binding specific 
DNA are sufficient to lose the function of the remaining 
wild-type p53. The p53 tetramer binds to its specific DNA 
using both of its dimers, which means that one mutant 
dimer present in the tetramer would be enough to abolish 
the binding and to impair the transcription activation func-
tion of p53 [22].
Importantly, families carrying missense mutations 
within the DNA-binding domain of TP53 show a higher 
penetrant cancer phenotype than families with protein-
truncating or protein-inactivating mutations [8]. Indeed, it 
has been reported that dominant-negative mutations con-
stitute the most severe mutations among missense muta-
tions and they are associated with an earlier tumor onset. 
In our series, two missense mutations (c.733G > A and 
c.743G > A) in the core domain were classified as dom-
inant-negative. These cases showed a high clinical sever-
ity, with an age of tumor onset of 4 and 12 years. The less 
severe alterations correspond to loss of function mutations 
that include nonsense mutations, frameshift mutations or 
genomic rearrangements, and they are usually associated 
with later tumor onset [8]. In this case, we showed a short 
inframe deletion, so we had to describe the phenotypic 
expression in this family in order to classify it as a severe 
or mild mutation.
As it is mentioned above, the novel inframe deletion was 
located in the DNA-binding domain. However, this deletion 
did not affect the residues responsible for the direct contact 
with DNA. The DNA sequencing and microsatellite study 
of p53 in the tumor of a family member suggested LOH 
of the TP53 wild-type allele. The LOH in the tumor sug-
gests that the deletion may not act in a dominant-negative 
way, since the loss of the wild-type allele was necessary for 
tumor development. In conclusion, based on variant seg-
regation, immunohistochemistry, loss of heterozygosity, in 
silico studies and late tumor onset in this family, this muta-
tion may be considered as a pathogenic variant that acts in 
a non-dominant negative way.
The higher penetrance and earlier tumor onset associ-
ated with dominant-negative TP53 mutations emphasizes 
the importance of defining novel TP53 mutations. We 
agree with Bougeard and col. on the suggestion of strati-
fying the clinical management of TP53 carriers accord-
ing to the class of their mutation [8]. Indeed, risk assess-
ment in families attending the genetic counseling, as well 
as possible predictive testing, must take into account the 
type of mutation. The severe dominant-negative missense 
mutations may constitute an argument for presymptomatic 
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testing in children and annual screening protocols. How-
ever, in this case presymptomatic tests are only justified in 
the adults from this family.
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